Stock Fundamentals

Company Information

Company Name
FibroGen Inc
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US31572Q8087
CIK: 0000921299
CUSIP: 31572Q808
Currency: USD
Full Time Employees: 225
Phone: 415 978 1200
Fiscal Year End: December
IPO Date: Nov 14, 2014
Description:

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. Its pipeline products include FG-3165 and FG-3175, an anti-GAL-9 antibody for treatment of solid tumors. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

Address:

350 Bay Street, San Francisco, CA, United States, 94133

Directors & Officers

Name Title Year Born
Mr. Thane Wettig CEO & Director 1965
Mr. David DeLucia Senior VP & CFO 1989
Mr. John Alden Corporate Secretary & General Counsel NA
Ms. Gaia Vasiliver-Shamis Director of IR & Communications - LifeSci Advisors NA

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
Armistice Capital, LLC 336.00K Jun 30, 2025 8.31% $0.03 -1.18%
Vanguard Group Inc 178.04K Jun 30, 2025 4.40% $0.00 -24.03%
PRIMECAP Management Company 89.70K Jun 30, 2025 2.22% $0.00 -40.06%
BlackRock Inc 84.75K Jun 30, 2025 2.10% $0.00 -10.69%
Marshall Wace Asset Management Ltd 72.30K Jun 30, 2025 1.79% $0.00 -18.31%
Geode Capital Management, LLC 44.04K Jun 30, 2025 1.09% $0.00 1.98%
HighTower Advisors, LLC 39.75K Jun 30, 2025 0.98% $0.00 145.65%
Goldman Sachs Group Inc 32.20K Mar 31, 2025 0.03% $0.00 -28.92%
Two Sigma Investments LLC 14.11K Jun 30, 2025 0.35% $0.00 -39.64%
State Street Corp 13.72K Jun 30, 2025 0.34% $0.00 -0.02%
Renaissance Technologies Corp 11.18K Jun 30, 2025 0.28% $0.00 -41.92%
UBS Group AG 10.29K Jun 30, 2025 0.25% $0.00 4.73%
Group One Trading, LP 7.21K Jun 30, 2025 0.18% $0.00 -15.05%
Morgan Stanley - Brokerage Accounts 1.66K Jun 30, 2025 0.04% $0.00 -57.54%
Tower Research Capital LLC 793.00 Jun 30, 2025 0.02% $0.00 0.00%
Advisor Group Holdings, Inc. 642.00 Jun 30, 2025 0.02% $0.00 -14.74%
Gfg Capital, LLC 507.00 Jun 30, 2025 0.01% $0.00 -1.17%
Bank of America Corp 443.00 Jun 30, 2025 0.01% $0.00 0.68%
Atlantic Trust Group, LLC 287.00 Jun 30, 2025 0.01% $0.00 0.00%
SBI Securities Co Ltd 152.00 Jun 30, 2025 0.00% $0.00 63.44%

Shares Statistics

Shares Outstanding: 4.05M
Shares Float: 3.58M
% Insiders: 165.60%
% Institutions: 2,801.00%
Short % Float: 3.31%

🏆 Top 10 Institutional Holders

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Armistice Capital, LLC 336.00K 8.31% ▼ 1.18% Jun 30, 2025
2 Vanguard Group Inc 178.04K 4.40% ▼ 24.03% Jun 30, 2025
3 PRIMECAP Management Company 89.70K 2.22% ▼ 40.06% Jun 30, 2025
4 BlackRock Inc 84.75K 2.10% ▼ 10.69% Jun 30, 2025
5 Marshall Wace Asset Management Ltd 72.30K 1.79% ▼ 18.31% Jun 30, 2025
6 Geode Capital Management, LLC 44.04K 1.09% ▲ 1.98% Jun 30, 2025
7 HighTower Advisors, LLC 39.75K 0.98% ▲ 145.65% Jun 30, 2025
8 Goldman Sachs Group Inc 32.20K 0.03% ▼ 28.92% Mar 31, 2025
9 Two Sigma Investments LLC 14.11K 0.35% ▼ 39.64% Jun 30, 2025
10 State Street Corp 13.72K 0.34% ▼ 0.02% Jun 30, 2025

Valuation Metrics

Enterprise Value: $80.63M
Trailing P/E: 0.00
Forward P/E: 61.35

Financial Highlights

Market Cap: $39.28M
EBITDA: $-58.06M
PEG Ratio: $0.00
Book Value: $-4.21
Earnings/Share: $-12.85
Profit Margin: 2,598.87%
Operating Margin: -499.07%
ROA (TTM): -18.42%
ROE (TTM): -1,015.79%
Revenue (TTM): $8.30M
Revenue/Share (TTM): $2.05
Earnings Growth (YOY): 53.60%
Revenue Growth (YOY): 774.80%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Download Financials (Excel)

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Earnings Per Share (EPS) History

Financial Ratios (Yearly)

Financial Ratios (Quarterly)

Earnings History

Balance Sheet (Yearly)

Financial Ratios

Date Current Ratio Debt/Equity Debt/Assets Interest Coverage Debt/EBITDA
2024-12-31 1.47x -0.32x 1.86x -18.24x -0.51x
2023-12-31 1.52x -0.42x 1.38x -39.87x -0.28x
2022-12-31 1.80x -0.48x 1.00x -209.05x -0.04x
2021-12-31 2.10x 0.05x 0.70x -134.01x -0.04x
2020-12-31 4.63x 0.03x 0.47x -79.88x -0.08x
2019-12-31 6.84x 0.06x 0.38x -31.05x -0.56x
2018-12-31 7.75x 0.04x 0.40x -7.89x -0.26x
2017-12-31 9.69x 0.13x 0.35x -12.63x -0.71x
2016-12-31 4.09x 0.91x 0.63x -5.00x -3.17x
2015-12-31 2.99x 0.33x 0.58x -7.04x -0.85x
2014-12-31 3.16x 0.44x 0.50x -4.51x -2.21x
2013-12-31 3.83x 1.21x 0.64x -0.74x 114.84x
2012-12-31 2.23x 0.99x 0.54x -2.72x -5.47x

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Nov 17, 2025 Thane Wettig N/A Purchase 2.70K $9.10 $24.57K
Nov 13, 2025 Thane Wettig N/A Purchase 1.00K $9.18 $9.18K
Jun 30, 2025 James A Schoeneck N/A Purchase 23.57K $5.07 $119.48K
Mar 24, 2025 Thane Wettig N/A Purchase 5.80K $8.75 $50.75K
Mar 20, 2025 James A Schoeneck N/A Purchase 10.00K $8.75 $87.50K

📦 Raw API Data (JSON Explorer)

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about FGEN.US!